Cas:460044-74-0 5-chloro-7-methoxy-1-benzofuran-2-carboxylic acid manufacturer & supplier

Chemical Name:5-chloro-7-methoxy-1-benzofuran-2-carboxylic acid

CAS.NO:460044-74-0

Synonyms:5-Chloro-7-methoxy-benzofuran-2-carboxylic acid

Molecular Formula:C₁₀H₇ClO₄

Molecular Weight:226.61300

HS Code:2932999099

Physical and Chemical Properties:

Melting point:N/A

Boiling point:385.5ºC at 760 mmHg

Density:1.463g/cm3

Index of Refraction:1.627

PSA:59.67000

Exact Mass:226.00300

LogP:2.79300

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 5-Chloro-7-methoxy-benzofuran-2-carboxylic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,5-Chloro-7-methoxy-benzofuran-2-carboxylic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,5-Chloro-7-methoxy-benzofuran-2-carboxylic acid Use and application,5-Chloro-7-methoxy-benzofuran-2-carboxylic acid technical grade,usp/ep/jp grade.

Related News: Jo Soden, Co-managing Director of Retrogenix, said ��We look forward to working with Resonant to deconvolute the targets for their antibodies. Resonant��s innovative platform is delivering functional therapeutic candidates at rapid pace and we welcome the opportunity to identify the specific, biologically-relevant targets which will help progress these leads towards promising new therapies for patients with cancer.�� 5-chloro-7-methoxy-1-benzofuran-2-carboxylic acid manufacturer As part of the agreement, ICIG will enter into a 5-year supply contract to provide Genzyme with materials needed for the production of eliglustat tartrate, an investigational treatment for Gaucher disease Type 1 that is currently in Phase III clinical trials. 5-chloro-7-methoxy-1-benzofuran-2-carboxylic acid supplier From the perspective of the overall life cycle of generic drugs from R & D to sales, with the expiration of patents, the business model for the production and marketing of generic pharmaceutical raw materials has changed, demand has increased, business potential has been realized quickly, and gross profit margins have shown a downward trend. 5-chloro-7-methoxy-1-benzofuran-2-carboxylic acid vendor Jo Soden, Co-managing Director of Retrogenix, said ��We look forward to working with Resonant to deconvolute the targets for their antibodies. Resonant��s innovative platform is delivering functional therapeutic candidates at rapid pace and we welcome the opportunity to identify the specific, biologically-relevant targets which will help progress these leads towards promising new therapies for patients with cancer.�� 5-chloro-7-methoxy-1-benzofuran-2-carboxylic acid factory Jo Soden, Co-managing Director of Retrogenix, said ��We look forward to working with Resonant to deconvolute the targets for their antibodies. Resonant��s innovative platform is delivering functional therapeutic candidates at rapid pace and we welcome the opportunity to identify the specific, biologically-relevant targets which will help progress these leads towards promising new therapies for patients with cancer.��